BrainStorm Cell Therapeutics, Inc. (BCLI) Signs MOU with PRC Clinical to Manage Upcoming Clinical Trial
Leading adult stem cell technology developer BrainStorm Cell Therapeutics announced it has signed a memorandum of understanding (MOU) with San Francisco Bay Area-based contract research organization (CRO) PRC Clinical, in anticipation of BrainCell’s planned Phase II multicenter ALS clinical trial in the U.S. BrainStorm chose PRC to manage its upcoming trial based on the organization’s comprehensive scope of support services, its experience with both orphan drug trials and neurological disease (specifically ALS), and its cutting-edge monitoring and management technologies. “PRC Clinical is delighted to have been selected as the CRO for this trial, and we are committed to providing BrainStorm’s…